ClinicalTrials.gg
Not yet recruitingNCT07320820QoL in LSSCUpdated Nov 18, 2026

Quality of Life and Functional Outcomes in Laryngeal Cancer Patients

An observational study in Laryngeal Carcinoma, Quality of Life (QOL) and Patient Satisfaction, sponsored by Saglik Bilimleri Universitesi. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Saglik Bilimleri Universitesi · Observational

How we know

Updated Nov 18, 2026Start date movedPrimary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
120
Ages
18 Years and older
Sex
All
01

Study summary

Laryngeal squamous cell carcinomas are head and neck malignancies that directly affect both swallowing and voice functions and are associated with a significant deterioration in patients' quality of life throughout the treatment process.

The aim of this study is to evaluate quality of life, voice and swallowing functions, pain, anxiety-depression levels, and patient satisfaction at the pre-treatment period and at the 3rd, 6th, and 12th months post-treatment in patients with laryngeal malignancies, using validated questionnaires, in order to:

Elucidate the course of functional recovery following treatment,

Individualize rehabilitation and follow-up strategies, and

Examine the relationship between functional outcomes and oncological survival.

02

Conditions studied

  • Laryngeal Carcinoma
  • Quality of Life (QOL)
  • Patient Satisfaction
  • Voice Quality
  • Swallowing Function
  • Pain Management
  • Anxiety Depression
03

In context

Laryngeal Neoplasms

258 studies on the registry are indexed under Laryngeal Neoplasms; 69 are open to participants now.

This study's planned enrollment of 120 is above the median of 100 across 61 observational studies indexed under Laryngeal Neoplasms.

Browse Laryngeal Neoplasms studies →

Lead sponsor

Saglik Bilimleri Universitesi is the lead sponsor of 458 studies on the registry; 124 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of patients diagnosed with laryngeal squamous cell carcinoma who are planned to undergo surgical treatment, radiotherapy, or chemoradiotherapy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years at the time of enrollment.
  • Histopathologically confirmed diagnosis of laryngeal squamous cell carcinoma.
  • Planned to undergo surgical treatment or radiotherapy/chemoradiotherapy as part of standard oncological care.
  • Willing and able to participate in the study and to provide written .
  • No history of psychiatric or neurological disorders that could impair comprehension, questionnaire completion, or study participation.

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years.
  • Presence of comorbid conditions that may independently affect swallowing or voice functions.
  • Patients who withdraw consent or request to discontinue participation during or after the treatment period.
  • History of psychiatric disorders or use of psychiatric medications that may interfere with study participation or completion of patient-reported outcome measures.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
120 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes

Groups and cohorts

  • Surgical Treatment Group

    This group includes patients with laryngeal squamous cell carcinoma who undergo primary surgical treatment, such as partial or total laryngectomy, with or without neck dissection, in accordance with standard oncological indications. Patients in this group may receive adjuvant radiotherapy or chemoradiotherapy when clinically indicated based on pathological findings.

    Other: Quality of Life Assessment · Other: Patient Satisfaction Assessment · Other: Swallowing Function Assessment · Other: Voice Assessment · Other: Pain Assessment · Other: Anxiety and Depression Assessment

  • Radiotherapy Group

    This group consists of patients with laryngeal squamous cell carcinoma treated with definitive radiotherapy as the primary treatment modality. Radiotherapy is delivered according to established clinical protocols, and no surgical intervention to the primary tumor is performed as the initial treatment.

    Other: Quality of Life Assessment · Other: Patient Satisfaction Assessment · Other: Swallowing Function Assessment · Other: Voice Assessment · Other: Pain Assessment · Other: Anxiety and Depression Assessment

  • Chemoradiotherapy Group

    This group includes patients with laryngeal squamous cell carcinoma who receive concurrent chemoradiotherapy as the primary treatment modality, typically for organ preservation purposes or in locally advanced disease. Chemotherapy is administered concurrently with radiotherapy in accordance with institutional and international treatment guidelines.

    Other: Quality of Life Assessment · Other: Patient Satisfaction Assessment · Other: Swallowing Function Assessment · Other: Voice Assessment · Other: Pain Assessment · Other: Anxiety and Depression Assessment

Interventions

  • OtherQuality of Life Assessment

    Quality of life will be assessed using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) and the Head and Neck Cancer-Specific Module (QLQ-H\&N35). The QLQ-C30 evaluates global health status, functional domains, and symptom scales, while the QLQ-H\&N35 provides disease-specific information related to head and neck cancer, including symptoms associated with swallowing, speech, pain, and social eating.

  • OtherPatient Satisfaction Assessment

    Patient satisfaction with cancer care will be evaluated using the EORTC In-Patient Satisfaction with Care Questionnaire (PATSAT-C33). This instrument assesses patients' perceptions of the quality of care, communication with healthcare professionals, and overall satisfaction with treatment and supportive care services.

  • OtherSwallowing Function Assessment

    Swallowing function will be assessed using the MD Anderson Dysphagia Inventory (MDADI) and the Eating Assessment Tool-10 (EAT-10). The MDADI is a disease-specific, patient-reported outcome measure that evaluates the impact of dysphagia on quality of life across emotional, functional, and physical domains. The EAT-10 is a symptom-specific screening tool designed to quantify the severity of swallowing difficulties and their effect on daily activities.

  • OtherVoice Assessment

    Voice-related outcomes will be evaluated using the Voice Handicap Index-10 (VHI-10), a validated patient-reported questionnaire that measures the perceived impact of voice disorders on functional, physical, and emotional aspects of daily life.

  • OtherPain Assessment

    Pain intensity will be assessed using the Visual Analog Scale (VAS), a widely used, validated tool that allows patients to rate their pain severity on a continuous scale, providing a quantitative measure of pain perception over time.

  • OtherAnxiety and Depression Assessment

    Psychological status will be evaluated using the Hospital Anxiety and Depression Scale (HADS), a validated self-report instrument designed to assess symptoms of anxiety and depression in medically ill populations, minimizing the influence of somatic symptoms related to physical illness.

06

What researchers measure

Primary outcomes

  1. Change in Head and Neck-Specific Quality of Life (EORTC QLQ-H&N35)

    Change in head and neck cancer-specific quality of life as assessed by the EORTC QLQ-H\&N35 questionnaire. The instrument evaluates symptoms and functional impairments related to head and neck cancer and its treatment; higher scores indicate greater symptom burden and worse quality of life.

    Time frame: Baseline (pre-treatment), 3 months, 6 months, and 12 months after completion of treatment. Type of Measure: Patient-reported outcome; continuous scale.

Secondary outcomes

  1. Change in Global Quality of Life (EORTC QLQ-C30)

    Change in global health status/quality of life score measured by the EORTC QLQ-C30 questionnaire. Higher scores on the global health status scale indicate better overall quality of life.

    Time frame: Baseline, 3 months, 6 months, and 12 months after completion of treatment.

  2. Change in Swallowing Function (MD Anderson Dysphagia Inventory - MDADI)

    Change in swallowing-related quality of life assessed by the MD Anderson Dysphagia Inventory (MDADI). Higher scores indicate better perceived swallowing function and quality of life.

    Time frame: Baseline, 3 months, 6 months, and 12 months after completion of treatment.

  3. Change in Patient Satisfaction (EORTC PATSAT-C33)

    Change in patient satisfaction with cancer care measured using the EORTC PATSAT-C33 questionnaire, which assesses satisfaction with physicians, nurses, organization of care, and overall treatment experience. Higher scores indicate greater patient satisfaction.

    Time frame: 3 months, 6 months, and 12 months after completion of treatment.

  4. Change in Dysphagia Severity (Eating Assessment Tool - EAT-10)

    Change in dysphagia symptom severity measured by the Eating Assessment Tool-10 (EAT-10). Higher scores indicate more severe swallowing difficulties.

    Time frame: Baseline, 3 months, 6 months, and 12 months after completion of treatment.

  5. Change in Voice-Related Handicap (Voice Handicap Index-10 - VHI-10)

    Change in patient-perceived voice handicap measured by the Voice Handicap Index-10 (VHI-10). Higher scores indicate greater perceived voice-related disability.

    Time frame: Baseline, 3 months, 6 months, and 12 months after completion of treatment.

  6. Change in Pain Intensity (Visual Analog Scale - VAS)

    Change in pain intensity measured using a Visual Analog Scale (VAS), ranging from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate greater pain intensity.

    Time frame: Baseline, 3 months, 6 months, and 12 months after completion of treatment.

  7. Change in Anxiety and Depression Levels (Hospital Anxiety and Depression Scale - HADS)

    Change in anxiety and depression symptoms measured by the Hospital Anxiety and Depression Scale (HADS), including HADS-Anxiety (HADS-A) and HADS-Depression (HADS-D) subscales. Higher scores indicate greater psychological distress.

    Time frame: Baseline, 3 months, 6 months, and 12 months after completion of treatment.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jul 2027, 6 months later.

Of 27 observational studies under Laryngeal Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 172. This study's planned 6 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: start Apr 2026 → Jan 2027 and primary completion Jan 2027 → Jul 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2025
First posted
Jan 6, 2026
StartEst.
Jan 2, 2027was Apr 2026
Primary completionEst.
Jul 2, 2027was Jan 2027
CompletionEst.
Dec 31, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Apr 2, 2026→Jan 2, 2027
Nov 18, 2026
Primary completion
Jan 2, 2027→Jul 2, 2027
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Start date Apr 2, 2026→Jan 2, 2027
    Primary completion Jan 2, 2027→Jul 2, 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07320820
Responsible party
Sumeyra DOLUOGLU (Associate Professor, Saglik Bilimleri Universitesi) — Principal investigator
First posted
Jan 6, 2026
Start date
Jan 2, 2027 (estimated)
Primary completion
Jul 2, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 18, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion